COFACE: PHARMACEUTICAL INDUSTRY REVIEW (Positive Outlook) By Saijil Singh, lead analyst, Coface South Africa Coface, the international credit insurer, has released its latest industry risk review covering the Pharmaceutical sector. The pharmaceutical industry is the largest of its kind in Africa, and has been identified by government as a key driver of economic growth; ensuring affordable healthcare is available to the private and public health sector. While the industry remains dominated by local companies, a number of multinationals distribute and some have become involved in local manufacturing. The country has a relatively well-developed industry, comprising a complex network of manufacturers, distributors and dispensers. Domestic companies produce, almost exclusively, generic pharmaceuticals, which are mainly targeted at the local market. Very little is exported, and what is, normally makes its way to other African countries. Government has earmarked the South African pharmaceutical industry as an area of growth. Preference will be given to local companies when it comes to national tenders for the supply of medicine. Change is likely to continue in the areas of funding and industry SENIOR BUSINESS DEVELOPMENT DIRECTOR SA AND SSA


is looking for a Gauteng based, Senior Business Development Director having a proven track record with more than 10 years of experience in Pharmaceutical Sales or Marketing Management and with a solid understanding of commercial principles. structure with a view to providing increased access to healthcare to all South Africans as efficiently and costeffectively as possible. Plans announced by government to build SA's first active public sector pharmaceutical ingredients (API) plant, in a joint venture between the South African government through Pelchem and a leading global pharmaceutical company Lonza. This is an example of a public-private partnership being created to reduce costs and increase accessibility. Government expects the development to boost South African drug makers and multinationals who have invested in local manufacturing. Companies operating in this sector normally secure large-scale and longterm tenders from the public sector, ensuring stable income levels and minimal risk. Margins are often predetermined and income guaranteed with minimal chance of a major changes in input costs. These companies are well secured and run minimal risk of failure, even though the sector traditionally operates on low margins. This position is suited to a candidate that preferably has extensive product knowledge, as you will be dealing with a wide variety of clients in the Pharmaceutical industry in both SA and SSA. The ideal candidate will already have well established relationships within the industry, and be in possession of a suitable tertiary qualification with excellent oral, presentation, and written communication skills. If you meet the abovementioned criteria, please register your CV with Job Code: 1209481 at https://quintiles.taleo.neticareersection/10000/jobsearch.ftl PIASA WELCOMES 2012/2013 EXECUTIVE COUNCIL AND PRESIDENT The Pharmaceutical Industry Association of South Africa (PIASA) is delighted to announce that Pierre Bosch, Area Director sub-Saharan Africa for Alcon Laboratories, has been re-elected as the industry body's president for 2012/2013. "Pierre has more than 20 years' experience in the pharmaceutical industry and has been a member of the PIASA Executive Council for the past four years. His knowledge of the industry, coupled with his enthusiasm, has added immense value to the team and we are delighted to welcome him as President for a second year," says Vicki St Quintin, COO for PIASA. Joining Bosch on the PIASA management council is Laura Engelbrecht-Joubert (Abbott Laboratories), Jonathan Louw (Adcock Ingram Healthcare) and Steve Speller (Servier). Other members of the executive council for 2012/2013, who will offer strategic direction and counsel to the association include: Guni Goolab (AstraZeneca Pharmaceuticals); Richard de Chastelain (Bayer Healthcare Pharmaceuticals); Barry Wren (Covidien); Kobus Venter (Janssen); Magnet de Wet (Key Oncologics); Timothy Kedijang (Novo Nordisk); and Amanda Wilde (Umsinsi Health Care). Pharmasales 9

You need to upgrade your Flash Player

You need to upgrade the version of your Flash Player to version 9 minimum.

Click here

Adobe Flash Player Download Center